Evidence map›Paper›PMID 35267638›Full record

ArticleCancers2022

Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center.

Henry Hiep Vo, Carrie Cartwright, I-Wen Song, Daniel D Karp, Graciela M Nogueras Gonzalez, Yuran Xie, Michael Karol, Matthew Hitron, David Vining, Apostolia-Maria Tsimberidou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. STAT3 signaling inhibitors for cancer treatment.Trends in pharmacological sciences · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Henry Hiep VoDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Carrie CartwrightDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
I-Wen SongDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.ORCID 0000-0003-1579-4328
Daniel D KarpDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Graciela M Nogueras GonzalezDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.ORCID 0000-0002-6350-2206
Yuran XieSumitomo Dainippon Pharma Oncology, 640 Memorial Drive, Cambridge, MA 02139, USA.
Michael KarolSumitomo Dainippon Pharma Oncology, 640 Memorial Drive, Cambridge, MA 02139, USA.
Matthew HitronSumitomo Dainippon Pharma Oncology, 640 Memorial Drive, Cambridge, MA 02139, USA.
David ViningDepartment of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Apostolia-Maria TsimberidouDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USSumitomo Dainippon Pharma (United States) · US

Funding

Supported in part by donor funds from Mr. and Mrs. Steven McKenzie, Mr. and Mrs. Zane W. Arrott, and Jamie's Hope for Dr. Tsimberidou's Personalized Medicine Program N/ASupport was provided in part by the National Institutes of Health/National Cancer Institute P30CA016672The study was primarily supported by Sumitomo Dainippon Pharma Oncology, Cambridge, Massachusetts, USA N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

advanced cancerBBI608checkpoint inhibitorclinical trialimmunotherapytargeted therapy

Identifiers

PMID35267638
PMCPMC8909492
OpenAlexW4220802533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.